Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track

Protagonist Therapeutics, Inc

2025-Q2 EPS reported -$0.73 revenue$33,867,000

Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.
Cash $673M as of June 30, sufficient for runway through at least end 2028.
NDA for icotrokinra (moderate-to-severe plaque psoriasis) submitted to FDA in July.
Rusfertide NDA for polycythemia vera expected Q4 2025; Phase 3 VERIFY data presented at ASCO.
Pipeline: PN-477 oral/subcutaneous triple agonist for obesity selected; PN-881 IL-17 antagonist.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.